0.00
전일 마감가:
$2.05
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$116.14M
수익:
$1.50M
순이익/손실:
$-64.59M
주가수익비율:
0.00
EPS:
-1.67
순현금흐름:
$-55.17M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
립 테라퓨틱스 Stock (LPTX) Company Profile
명칭
Leap Therapeutics Inc
전화
617 252 4343
주소
47 THORNDIKE STREET, CAMBRIDGE, MA
LPTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
LPTX
Leap Therapeutics Inc
|
0.00 | 116.14M | 1.50M | -64.59M | -55.17M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
립 테라퓨틱스 Stock (LPTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-01-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | 개시 | Rodman & Renshaw | Buy |
| 2021-10-04 | 개시 | Mizuho | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2020-06-29 | 개시 | Piper Sandler | Overweight |
| 2020-02-11 | 개시 | Robert W. Baird | Outperform |
| 2019-11-15 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-09-13 | 재개 | Raymond James | Outperform |
| 2017-03-07 | 개시 | Ladenburg Thalmann | Buy |
모두보기
립 테라퓨틱스 주식(LPTX)의 최신 뉴스
Can Leap Therapeutics Inc. (5MC) stock withstand sector downturnsTreasury Yields & Fast Entry Momentum Trade Alerts - Newser
Can Leap Therapeutics Inc. (5MC) stock attract analyst upgradesShort Setup & Real-Time Volume Triggers - Newser
Is Leap Therapeutics Inc. stock attractive for ETFsJuly 2025 Snapshot & Entry and Exit Point Strategies - Newser
How Leap Therapeutics Inc. (5MC) stock performs during market turbulenceJuly 2025 Sentiment & Weekly Market Pulse Alerts - Newser
Is Leap Therapeutics Inc. (5MC) stock undervalued historically2025 Investor Takeaways & Target Return Focused Picks - Newser
Will Leap Therapeutics Inc. (5MC) stock benefit from sector leadershipQuarterly Trade Review & Technical Pattern Based Buy Signals - Newser
Why Leap Therapeutics Inc. (5MC) stock could be next leaderTrade Risk Assessment & Accurate Technical Buy Alerts - Newser
Is Leap Therapeutics Inc. (5MC) stock a buy during volatile markets - Newser
Why ETFs are accumulating Leap Therapeutics Inc. (5MC) stockQuarterly Trade Report & Comprehensive Market Scan Insights - Newser
Promising Manufacturing Stocks To Watch TodayNovember 14th - MarketBeat
Stop Loss: Is Leap Therapeutics Inc. stock near bottom after declineWeekly Profit Recap & Fast Moving Trade Plans - moha.gov.vn
Manufacturing Stocks To Add to Your WatchlistNovember 13th - MarketBeat
CYPH: Cypherpunk Technologies Inc.Full Company Report - Zacks Investment Research
Small Cap Stocks To Keep An Eye OnNovember 18th - MarketBeat
[Form 4] LEAP THERAPEUTICS, INC. Insider Trading Activity - Stock Titan
[Form 3] LEAP THERAPEUTICS, INC. Initial Statement of Beneficial Ownership - Stock Titan
Will Leap Therapeutics Inc. (5MC) stock see valuation expansionQuarterly Earnings Report & Consistent Profit Trading Strategies - newser.com
Cypherpunk Technologies modifies warrant agreement with Winklevoss Capital By Investing.com - Investing.com Australia
What analyst consensus implies for Leap Therapeutics Inc. (5MC) stockJuly 2025 Decliners & Target Return Focused Picks - newser.com
Cypherpunk Technologies modifies warrant agreement with Winklevoss Capital - Investing.com India
Cypherpunk Technologies Modifies Warrant Agreement with Winklevoss - TipRanks
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cypherpunk Technologies Inc. (NASDAQ: CYPH) - marketscreener.com
Why Leap Therapeutics Inc. (5MC) stock remains stableMarket Volume Summary & Real-Time Buy Zone Alerts - newser.com
Is Leap Therapeutics Inc. (5MC) stock a top dividend aristocrat candidateEarnings Risk Report & High Return Stock Watch Alerts - newser.com
What downside risks could hit Leap Therapeutics Inc. (5MC) stockOil Prices & Target Return Focused Stock Picks - newser.com
Can swing trading help recover from Leap Therapeutics Inc. losses - newser.com
Why Leap Therapeutics Inc. stock is popular among millennialsJuly 2025 Trade Ideas & Smart Swing Trading Techniques - newser.com
Cypherpunk (CYPH) Stock: Doubles Down on Zcash With $18M Purchase as Privacy Coin Surges 140% - parameter.io
Leap Therapeutics, Inc.Cypherpunk Purchases Additional $18 Million of ZEC, Bringing Total Network Percentage to 1.43% - MarketScreener
Identifying reversal signals in Leap Therapeutics Inc.Portfolio Risk Summary & Fast Entry Momentum Alerts - newser.com
What RSI levels show for Leap Therapeutics Inc. (5MC) stockMarket Sentiment Review & Risk Controlled Daily Trade Plans - newser.com
Will Leap Therapeutics Inc. (5MC) stock beat Nasdaq index returnsWeekly Trend Report & Risk Adjusted Swing Trade Ideas - newser.com
CYPH Stock Price and Chart — NASDAQ:CYPH - TradingView
How Leap Therapeutics Inc. (5MC) stock performs in easing cyclesPortfolio Value Report & Free Safe Entry Trade Signal Reports - newser.com
립 테라퓨틱스 (LPTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
립 테라퓨틱스 주식 (LPTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| CAVANAUGH JAMES H | Director |
Nov 17 '25 |
Sale |
3.14 |
261,840 |
822,178 |
0 |
| ONSI DOUGLAS E | CEO,CFO,Pres.,GC,Treas.&Sec. |
Nov 17 '25 |
Sale |
3.14 |
676,319 |
2,123,642 |
2,136 |
자본화:
|
볼륨(24시간):